



the mouth with 5-10cc of 1% toluidine blue solution for 30 sec followed by 1% acetic acid solution rinse for 1 min and then rinse with water.<sup>23</sup> The lesion appears pale blue to dark blue in colour depending up on the DNA content present at the site as shown in figure 1. Several studies have evaluated the use of TB as an adjunct in oral cancer screening along with several limitations. Lingen et al listed the limitations as – absence of randomized controlled trials, lack of histological diagnosis as a gold standard and variability in methods of application.<sup>12</sup> Various researchers have putforth that only dark blue staining should be regarded as positive.<sup>24</sup> Studies assessing TB has shown sensitivity 97% - 93% and specificity 92.9%- 73.3%.<sup>25-26</sup> TB should not be used alone but along with other techniques as it can help to localize areas for biopsy or brush biopsy.



Fig.1. Toluidine Staining. A) Buccal mucosa before staining and B) Buccal mucosa after staining.

Lugols solution was introduced by Camillo Golgi. It is used for demarcation of the malignant change producing a brown black stain when iodine reacts with the glycogen content. It helps in differentiating the inflammatory epithelium and normal epithelium.<sup>27</sup> The test starts with 1% acetic acid rinse for 20 sec and then rinse with water followed by application of Lugol's Iodine at the lesion with cotton pellet for 10-20 secs.<sup>28</sup> Double staining i.e. with TB and LI serves as useful adjunct in the diagnosis malignant lesions as poorly differentiated lesions do not have glycogen content and therefore do not take up Lugol's iodine stain.

**Chemiluminescence- Reflective Tissue Fluorescence**

Chemiluminescence is production of light during a chemical reaction. It is being used in the USA since November 2001. It is easy, fast, safe, painless and non invasive system. It consists of a hand held device, disposable light sticks that emit light at wavelength of 430-580nm. The most well known device working on this principle is Vizilite. It involves the use of 1% acetic acid solution rinse for 1 min to remove surface debris followed by blue-white light illumination. The normal mucosa absorbs the light and dysplastic epithelium reflects the light as shown in figure 2. Normal epithelium appears bluish and the dysplastic epithelium appears acetowhite (distinctly white) as shown in figure 3. Early diagnosis of oral cancer can be improved using tolonium chloride.<sup>29</sup> New modified system MicroLux DL has been introduced which uses battery powered fiberoptic visible light source instead of Chemiluminescence.<sup>30</sup>




Fig 2. Mechanism of Chemiluminescence. A) Normal epithelium absorbs Vizilite illumination and appears dark. B) Dysplastic epithelium reflects Vizilite illumination and appears white




Fig 3. Chemiluminescence using vizilite. A) Lesion under incandescent light. B) Acetowhite lesion under blue-white light.

**Auto Fluorescence- Narrow Emission Tissue Fluorescence**

Auto Fluorescence is the alteration in the interaction of light and epithelium due to changes in structure and metabolism of epithelium.<sup>31</sup> Fluorescence involves the

exposure of tissues to a variety of excitation wavelengths so that there is dissimilarity between normal and dysplastic tissues.<sup>12</sup> VEL scope is the best known autofluorescence tool to aid in early finding of oral cancer.<sup>32</sup> It is a portable device that allows direct visualization of the lesion. The hand held device acts as a light source and the clinician can view through the protected eyepiece (Fig.4). The device provides intense blue excitation light (400-460nm) under which normal mucosa emits pale green auto fluorescence and the dysplastic area absorbs the light and appears dark (Fig 5). The sensitivity ranges from 97% to 98% and specificity ranges from 94% to 100%.<sup>28</sup>



Fig 4. VELscope hand held device




Fig 5. Auto Fluorescence using VELscope. A) Tissue under normal light. B) VELscope shows full extent of the lesion.

**Auto Fluorescence Spectroscopy**

The system consists of small optical fibre which generates a range of excitation



wavelengths and a spectrograph which receives and records on a computer and analyse spectra of reflected fluorescence from the tissue. It is very accurate in distinguishing the normal mucosa from the dysplastic mucosa but as the optical fibre is small in size therefore can analyse a small lesion with well defined boundaries. Research is required in spectroscopy for better clinical application.<sup>31</sup>

### Salivary analysis

Saliva as a diagnostic tool for detection of oral cancer is the latest concept. It is a non invasive, easy to collect and inexpensive molecular marker for oral cancer detection. The principle of analysis is based on the fact that the salivary composition is altered. Analysis of salivary macromolecules, enzymes, cytokines, growth factors, metalloproteases, endothelin, telomerase, cytokeratins, mRNA and DNA transcriptase is done.<sup>33</sup> High salivary counts of bacteria such as *Campylobacter gingivalis*, *Prevotella melaninogenica* and *Streptococcus mitis* is present in patients with oral cancer.<sup>23</sup> However further studies are required in the field of salivary analysis.

### Optical Coherence Tomography

It is a non invasive method to spot areas of inflammation, dysplasia and cancer by recording surface reflections to construct a cross-sectional image of the tissue. The use of surface Plasmon resonant gold nanoparticles enhances the image.<sup>34</sup> A latest study confirms the viability of using OCT to recognize tissue and cellular changes in malignant cells. But it does not provide definitive diagnosis and also can not differentiate between the lesions.<sup>35</sup>

### DNA Ploidy

It measures the nuclear DNA content to measure cell potential to transform into malignant cell. The cytological samples after staining with Feulgen dye are evaluated with a reference set of cells and a computer assisted analysis identifies difference of cellular DNA content. Cancer succession is contribute by genomic instability and dysplastic lesions are differentiated by atypical DNA content.<sup>36</sup>

### Conclusion

Early detection of oral cancer is important for overall survival of the patient as generally it is diagnosed at late stage. To improve the

patient outcome for screening of pre-malignancy condition, non-invasive techniques of diagnosis are very important as the patient might not be willing for any invasive technique when there are no clinical signs of dysplastic lesions that might lead to malignancy. Several researches are being done to look for a better and faster non-invasive diagnostic aid for oral cancer.

### References

1. Who World Cancer Report 2014
2. Sharma N, Mubeen. Non Invasive Diagnostic Tools In Early Detection Of Oral Epithelial Dysplasia. *J Clin Exp Dent*. 2011;3(3):E184-8
3. Cancer Control Knowledge Into Action. Who Guide For Effective Prog. Module 42008
4. Mehrotra R, Gupta DK. Exciting New Advances In Oral Cancer Diagnosis: Avenues To Early Detection
5. Kusukawa J, Suefuji Y, Ryu F, Noguchi R, Iwamoto O, Kameyan T. Dissemination Of Cancer Cells Into Circulation Occurs By Incisional Biopsy Of Oral Squamous Cell Carcinoma. *J Oral Pathol Med* 2000, 29:303-7
6. Gaikwad P, Hiremath SK, Singh S. Advancement In Diagnostic Aids For Oral Premalignant Lesions: A Review. *Journal Of Dental Sciences And Oral Rehabilitation* 2013; Jan-March
7. Sharma N, Fahmi N. Diagnostic Aids Of Precancerous Oral Lesions. *Int J Of Science Study* 2014 Vol 2 Issue 5
8. Shugars DC, Patton LL. Detecting, Diagnosing, And Preventing Oral Cancer. *Nurse Pract* 1997;22(6):105, 109-10, 113-5 Passim
9. Silverman S. Early Diagnosis Of Oral Cancer. *Cancer* 1988; 62(8 Suppl):1796-9
10. Sandler HC. Cytological Screening For Early Mouth Cancer. *Cancer* 1962; 15:1119-24
11. Thomson PJ. Field Change And Oral Cancer: New Evidence For Widespread Carcinogenesis. *Int J Oral Maxillofac Surg* 2002;17(2):79-87
12. Lingen MW Et Al. Critical Evaluation Of Diagnostic Aids For The Detection Of Oral Cancer. *Oral Oncol* (2007), Doi:10.1016/j.oraloncology.2007.06.011
13. Messadi DV. Diagnostic Aids For Detection Of Oral Precancerous Conditions. *Int J Of Oral Science* 2013;5,59-65
14. Christian DC. Computer-Assisted Analysis Of The Oral Brush Biopsies At An Oral Cancer Screening Program. *J Am Dent Assoc* 2002;133:357-62
15. Scheifele C, Schmidt-Westhausen Am, Dietrich T, Reichart PA. The Sensitivity And Specificity Of The Oral Cdx Technique: Evaluation Of 103 Cases. *Oral Oncol* 2004;40:824-8.
16. Eisen D, Frist S. The Relevance Of The High Positive Predictive Value Of The Oral Brush Biopsy. *Oral Oncol* 2005;41:753-5.
17. Bench MK. Oral Brush Biopsies. *J Am Dent Assoc* 2006;137:294.
18. Scuibba JJ. Improving Detection Of Precancerous And Cancerous Oral Lesions. Computer-Assisted Analysis Of The Oral Brush Biopsy. U.S. Collaborative Oral Cdx Study Group. *J Am Dent Assoc*. 1999;130(10):1445-57
19. Trullenque-Eriksson A, Munoz-Corcuera M, Campo-Trapero J, Cano-Sanchez J, Bascones- Martinez A. Analysis Of New Diagnostic Methods In Suspicious

Lesions Of The Oral Mucosa. *Med Oral Patol Oral Cir Bucal*. 2009; 14(5): E210-6.

20. Richart, RM. A Clinical Staining Test For In Vivo Delineation Of Dysplasia And Carcinoma In Situ. *Am J Obst Gynecol* 1963; 86:703
21. Mashberg A: Toluidine Blue. *J Can Dent Assoc* 1995, 61(11):922-944.
22. Awan KH, Yang YH, Morgan PR Et Al. Utility Of Toluidine Blue As A Diagnostic Adjunct In The Detection Of Potentially Malignant Disorders Of The Oral Cavity—A Clinical And Histological Assessment. *Oral Dis* 2012; 18(8): 728–733
23. Scully Crispian, Bagan JV, Hopper C, Epstein Jb. *Oral Cancer : Current And Future Diagnostic Techniques Am J Dent* 2008;21:199-209
24. Huber MA, Bsoul SA, Terezhalmay GT. Acetic Acid Wash And Chemiluminescent Illumination As An Adjunct To Conventional Oral Soft Tissue Examination For The Detection Of Dysplasia: A Pilot Study. *Quintessence Int* 2004;35(5):378–84. [PubMed: 15130078]
25. Patton LL, Epstein JB, Kerr AR. Adjunctive Techniques For Oral Cancer Examination And Lesion Diagnosis: A Systematic Review Of The Literature. *J Am Dent Assoc* 2008; 139(7): 896–905.
26. Su W, Yen AM, Chiu Sy Et Al. A Community-Based Ret For Oral Cancer Screening With Toluidine Blue. *J Dent Res* 2010; 89(9): 933–937.
27. Epstein JB, Scully C, Spinelli J. Toluidine Blue And Lugol'S Iodine Application In The Assessment Of Oral Malignant Disease And Lesions At Risk Of Malignancy. *J Oral Pathol Med* 1992;21:160-63.
28. Elongovan S, Hasan S. Conventional And Advanced Diagnostic Aids In Oral Cancer Screening – The Journey So Far. *Int J Pharm Pharm Sci*, 2015; 7(1): 29-33
29. Epstein JB, Silverman S Jr, Epstein JD, Lonky SA, Bride MA: Analysis Of Oral Lesion Biopsies Identified And Evaluated By Visual Examination, Chemiluminescence And Toluidine Blue.
30. Mehrotra R, Hullmann M, Smeets R, Reichert TE, Driemel O: Oral Cytology Revisited. *J Oral Pathol Med* 2009, 38:161-6.
31. De Veld DC, Wijtes MJ, Sterenberg HJ, Roodenburg JL: The Status Of In Vivo Autofluorescence Spectroscopy And Imaging For Oral Oncology. *Oral Oncol* 2005, 41:117-131.
32. Cheng LYS, Wright J. Advances In Diagnostic Adjuncts For Oral Squamous Cell Carcinoma. *The Open Pathology J* 2011;5:3-7
33. Naghipur S. A Review Of Diagnostic Aids For Oral Cancer Screenings In General Practice Dentistry. *Int Dent J Of Students Research* 2014;2(2):10-16
34. Kim CS, Wilder-Smith P, Ahn YC, Liaw LH, Chen Z, Kwon Yj. Enhanced Detection Of Early-Stage Oral Cancer In Vivo By Optical Coherence Tomography Using Multimodal Delivery Of Gold Nanoparticles. *J Biomed Opt* 2009;14(3):034008
35. Jerjes W, Üpile T, Conn B, Betz Cs, McKenzie G, Radhi H, Vourvachis M, El Maaytah M, Sandison A, Jay A, Hopper C: In Vitro Examination Of Suspicious Oral Lesions Using Optical Coherence Tomography. *Br J Oral Maxillofac Surg* 2010, 48:18-25.
36. Bradley G, Odell EW, Raphael S, Ho J, Le LW, Benchimol S, Et Al. Abnormal Dna Content In Oral Epithelial Dysplasia Is Associated With Increased Risk Of Progression To Carcinoma. *Br J Cancer* 2010;103(9):1432-42.

